Medical Costs of Respiratory Syncytial Virus–Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019 - 09/07/24
, Yingtao Zhou, MPH 1, Ayzsa Tannis, MPH 1, Mary Allen Staat, MD, MPH 2, Marilyn Rice, MS 2, Julie A. Boom, MD 3, Leila C. Sahni, PhD, MPH 3, Rangaraj Selvarangan, PhD 4, Christopher J. Harrison, MD 5, 6, Natasha B. Halasa, MD, MPH 7, Laura S. Stewart, PhD 7, Geoffrey A. Weinberg, MD 8, Peter G. Szilagyi, MD, MPH 8, Eileen J. Klein, MD, MPH 9, Janet A. Englund, MD 9, Brian Rha, MD, MPH 10, Joana Y. Lively, MPH 10, Ismael R. Ortega-Sanchez, PhD 1, Meredith L. McMorrow, MD, MPH 1, 11, Heidi L. Moline, MD, MPH 1, 11Abstract |
Objective |
To assess medical costs of hospitalizations and emergency department (ED) care associated with respiratory syncytial virus (RSV) disease in children enrolled in the New Vaccine Surveillance Network.
Study design |
We used accounting and prospective surveillance data from 6 pediatric health systems to assess direct medical costs from laboratory-confirmed RSV-associated hospitalizations (n = 2007) and ED visits (n = 1267) from 2016 through 2019 among children aged <5 years. We grouped costs into categories relevant to clinical care and administrative billing practices. We examined RSV-associated medical costs by care setting using descriptive and bivariate analyses. We assessed associations between known RSV risk factors and hospitalization costs and length of stay using χ2 tests of association.
Results |
The median cost was $7100 (IQR $4006-$13 355) per hospitalized child and $503 (IQR $387-$930) per ED visit. Eighty percent (n = 2628) of our final sample were children aged younger than 2 years. Fewer weeks’ gestational age was associated with greater median costs in hospitalized children (P < .001, ≥37 weeks of gestational age: $6840 [$3905-$12 450]; 29-36 weeks of gestational age: $7721 [$4362-$15 274]; <29 weeks of gestational age: $9131 [$4518-$19 924]). Infants born full term accounted for 70% of the total expenditures in our sample. Almost three quarters of the health care dollars spent originated in children younger than 12 months of age, the primary age group targeted by recommended RSV prophylactics.
Conclusions |
Reducing the cost burden for RSV-associated medical care in young children will require prevention of RSV in all young children, not just high-risk infants. Newly available maternal vaccine and immunoprophylaxis products could substantially reduce RSV-associated medical costs.
Le texte complet de cet article est disponible en PDF.Keywords : RSV, cost, emergency department, hospitalizations, pediatrics
Abbreviations : ARI, ED, ICU, IPT, LOS, NVSN, RSV
Plan
Vol 271
Article 114045- août 2024 Retour au numéro
Article précédent
- Use of Initial Endotracheal Versus Intravenous Epinephrine During Neonatal Cardiopulmonary Resuscitation in the Delivery Room: Review of a National Database
- Cecilie Halling, Sara Conroy, Tia Raymond, Elizabeth E. Foglia, Mary Haggerty, Linda L. Brown, Myra H. Wyckoff, American Heart Association’s Get With The Guidelines–Resuscitation Investigators
- Isolated Hydronephrosis and Urinary Tract Infection by Two Years of Age: A Population-Based Study
- Gilad Hamdani, Noga Yaniv, Shoval Shoham, Yael Borovitz, Shelly Levi, Daniel Landau, Amit Dagan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?